SciBX: Science-Business eXchange
As published Thursday, November 20, 2014
By Benjamin Boettner, Senior
Although targeting proteins involved in cell division is
falling out of fashion in cancer research because of the difficulty of
distinguishing between diseased and normal cells, several companies are still
exploring enzymes that could be tractable targets. A new inhibitor of TOPK-an enzyme involved in
mitosis-could provide an option for cancers unserved by targeted therapies,
based on findings in mice that liposomal delivery reduces the compound's
toxicity, keeps it away from hematopoietic cells and increases its therapeutic
Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute’s translational potential.
A paper-based diagnostic using RNA switches could provide an easily distributed, rapid test for infectious diseases in point-of-care settings.
HemoShear's in vitro tumor model shows a new application for its tissue modeling technology and could open it to business from oncology companies.